1. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab.
- Author
-
Zimmerman LA, Zalieckas JM, Shamberger RC, and Bousvaros A
- Subjects
- Adolescent, Antibodies, Monoclonal, Humanized therapeutic use, Child, Colitis, Ulcerative surgery, Crohn Disease surgery, Female, Gastrointestinal Agents therapeutic use, Humans, Ileostomy, Ileus chemically induced, Intestinal Obstruction chemically induced, Male, Postoperative Complications epidemiology, Prospective Studies, Surgical Stomas, Antibodies, Monoclonal, Humanized adverse effects, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy, Gastrointestinal Agents adverse effects, Postoperative Complications chemically induced
- Abstract
Background: Vedolizumab is a biologic, which inhibits leukocyte adhesion in the gut and is used to treat ulcerative colitis (UC) and Crohn's disease (CD). Little is known of the surgical outcomes in patients treated with vedolizumab. We reviewed the postoperative complications in a cohort of pediatric UC and CD patients treated with vedolizumab., Methods: We identified pediatric UC and CD patients treated with vedolizumab at our institution from 2014 to 2016. We compared postoperative outcomes in the vedolizumab exposed group to a cohort of vedolizumab naïve patients who required diverting ileostomy., Results: Of the 31 patients who were treated with vedolizumab, 13 patients required surgery. Eight of 13 (62%) vedolizumab exposed patients had a postoperative complication, including mucocutaneous separation at the stoma (3), readmission for pain/dehydration (2), bowel obstruction at the ostomy, and intraoperative colonic perforation. In comparison, four of 16 (25%) vedolizumab naive patients had a postoperative complication, including readmission for ileus and for high stoma output with mucocutaneous separation. p=0.07., Conclusions: At our institution, patients treated with vedolizumab prior to surgery have a high prevalence of postoperative complications, notably mucocutaneous separation of the stoma. A prospective, multicenter study is needed to determine if these observed complications are attributable to vedolizumab., Level of Evidence: Level III., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF